Dr. Julie Meigs has over 20 years of intellectual property experience in life sciences after beginning her career as a research scientist in the biotech industry. Julie helps clients design and implement strong patent portfolios that support new product development through to market launch. She equally understands both technology and business challenges that life sciences companies face, and clients trust Julie to help them successfully navigate in a competitive space. 

Julie’s practice focuses on the design and implementation of global patent strategies, including life cycle and risk management. She advises clients in a wide range of patent-related areas, including preparation and prosecution of US and international patent applications, freedom to operate and invalidity analyses, due diligence, competitor activity, and strategic partnerships.

Clients respect Julie’s proactive approach to securing strong patents, her ability to tackle complex IP issues, and her leadership of an efficient team. Julie adds value by keeping a sharp eye on clients’ commercial goals.

Julie’s credibility extends beyond her legal expertise. She has earned the confidence of scientists as well as lawyers, and she skillfully communicates with both inventors and corporate executives.  In particular, she has technical experience in the areas of oncology, immunology, neuroscience, infectious disease, biologics, antibodies, vaccines, diagnostics, gene editing and genomics, stem cell biology and agricultural biotechnology.

Publications

  • Recent Legal Publications & Presentations:
    • Moore, J. and Meigs, J., “Leveraging Orphan Drug Designation and Patent Protection for Increased Investment,” IP WatchDog, Jan 2020.
  • Research Papers:
    • Broadus J., et al. (1999) The Drosophila bFTZ-F1 orphan nuclear receptor provides competence for stage-specific responses to the steroid hormone ecdysone. Molecular Cell 3:143-149.
    • Broadus J., et al. (1998) Staufen-dependent localization of prospero mRNA contributes to neuroblast daughter-cell fate. Nature 391:792-795.
    • Broadus J. & Doe C.Q. (1997) Extrinsic cues, intrinsic cues, and microfilaments regulate asymmetric protein localization in Drosophila neuroblasts. Current Biology 7:827-835.
    • Broadus J., et al. (1995) New neuroblast markers and the origin of the aCC/pCC neurons in the Drosophila central nervous system. Mechanisms of Development 54:1-10.
    • Broadus J. & Doe C.Q. (1995) Evolution of neuroblast identity: seven-up and prospero expression reveal homologous and divergent cell fates in Drosophila and Schistocerca. Development 121:3989-3996.
    • Hawrylak N., Ghosh P., Broadus J., Lauterbur P.C. & Greenough W.T. (1993) Nuclear magnetic resonance (NMR) imaging of iron oxide-labeled neural transplants. Experimental Neurology 121:181-192.
  • Reviews:
    • Fuerstenberg S., Broadus J. & Doe C.Q. (1998) Asymmetry and cell fate in the Drosophila embryonic CNS. International Journal of Developmental Biology 42(3):143-149.
  • Book Chapters:
    • Broadus J. & Spana E.P. (1999) Asymmetric divisions and cell fate specification in the Drosophila central nervous system. In Cell Fate and Lineage Determination, S.A. Moody, Editor. 1999, Academic Press: San Diego. pp. 273-285.
  • Published Patent Applications:
    • Broadus J., et al. Insect nuclear receptor genes and uses thereof, PCT International Publication No. WO 02/077157.
    • Broadus J., et al., Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof, U.S. Patent Application Publication No. 20020160934

Professional and Civic Activities

  • American Intellectual Property Law Association
  • BIO Start Up Stadium Competition
  • American Bar Association
  • North Carolina Bar Association (Citizen-Lawyer Committee Member)
  • North Carolina Association of Women Attorneys
  • North Carolina Biosciences Organization (Board of Directors)

Experience

Any result the lawyer or law firm may have achieved on behalf of clients in other matters does not necessarily indicate similar results can be obtained for other clients.

  • Managed patent portfolio that supported acquisition of a life sciences startup by big pharma in a deal totaling up to $10 billion.
  • IP strategy and patent procurement for global pharmaceutical companies, particularly in the area of cancer biologics. 
  • IP strategy and patent procurement for global agricultural biotechnology companies.
  • Pro bono IP counsel as part of University of California Hastings’ Startup Legal Garage, an innovative program connecting law students with biotech and tech startups.
  • Recipient of a 2016 Client Choice Award for excellent client care and high quality legal service.